Summary The effects of different doses of angiotensin 11 (0.02 to 0.5 jlg kg-' min-' on mean arterial blood pressure, tissue blood flow and tissue vascular resistance were investigated in BD9 rats. Blood flow was measured using the uptake of 12511 or 4C-labelled iodoantipyrine ('25I-IAP and '4C-IAP). Spatial heterogeneity of blood flow within tumours, before and after angiotensin II infusion, was also measured using '4C-IAP and an autoradiographic procedure. Mean arterial blood pressure rose steeply with angiotensin II dose. Blood flow to skeletal muscle, skin overlying the tumour, contralateral skin, small intestine and kidney tended to decline in a dose-dependent manner. Blood flow to the tumour was also reduced (to 80% of control values) but there was no dose response. Blood flow to the heart was slightly increased and blood flow to the brain was unaffected by angiotensin II. Vascular resistance, in all tissues, was increased by angiotensin II infusion. The increase in tumour tissue was similar to that found in skeletal muscle and small intestine and is likely to be caused by a direct vasoconstricting effect of the drug rather than autoregulation of tumour blood flow in the face of an increase in perfusion pressure. The reduction in overall blood flow at the highest perfusion pressure was due to a preferential effect of angiotensin II at the tumour periphery. These results show that some tumours, at least, can respond directly to the effects of vasoactive agents.
Selective manipulation of tumour blood flow using vasoactive agents is potentially useful for some forms of therapy. In particular, an increase in tumour blood flow relative to surrounding normal tissue would improve the delivery of anticancer drugs. An increase in flow would also improve oxygen delivery to tumours, resulting in improved oxygenation and thus response to radiotherapy, as long as any simultaneous increase in oxygen consumption did not counteract the effect.
Blood flow through a tissue depends upon the perfusion pressure and the resistance to flow arising from the viscosity of blood and the geometry of the blood vessels (blood flow = arteriovenous pressure difference + vascular resistance). Blood flow to experimental tumours has been found to respond readily to changes in systemic arterial blood pressure. For instance, controlled bleeding of rats causes a progressive decline in tumour blood flow (Vaupel, 1975; Tozer et al., 1990a) . Blood flow to such tumours is also substantially reduced following high doses of vasodilators such as hydralazine which dramatically lower systemic blood pressure (e.g. Horsman et al., 1989) . Such studies have led to the suggestion that tumour vascular resistance is minimally affected by vasoactive drugs (e.g. Horsman et al., 1989; Trotter & Chaplin, 1991) . However, the degree to which tumour vessels respond to drugs will also be dependent on other factors such as tumour size, site and the proportion of normal blood vessels incorporated into the tumour mass. Thus, one of the aims of the present study was to determine the reactivity of tumour blood vessels to a particular vasoactive agent, angiotensin II. Angiotensin II is an endogenous peptide produced locally in blood vessels and other tissues by the action of renin and angiotensin converting enzyme on angiotensin I. It is a potent arteriolar vasoconstrictor which acts by binding to specific receptors located on the smooth muscle cells. It is generally supposed that the poorly differentiated blood vessels of tumours would be lacking in such structures. Therefore, the rationale for using angiotensin II is that vasoconstriction in most normal tissues would increase the perfusion pressure to the tumour with little or no direct vasoconstriction of the blood vessels supplying the tumour. The consequence would be an increase in blood flow to the tumour. Again, this argument may be too simplistic.
The first reports of using angotensin II in oncology were as an aid to tumour imaging by angiography (Kaplan & Bookstein, 1972 ; Ekelund & Lunderqvist, 1974) . Later, Jirtle et al. (1978) found that constant intravenous infusion of high dose angiotensin 11 (1.4 Ag min ') into tumour-bearing rats caused a 4-fold increase in blood flow to the tumour growing in the mammary gland relative to that in the normal mammary gland and skin although the absolute blood flow to the tumour was decreased from 1.3 ml g -min ' to 0.8 ml g' min-'. Subsequent studies have shown that angiotensin IIinfusion can increase absolute, as well as relative, blood flow in some tumour systems (Tokuda et al., 1990; Hori et al., 1991; Tanda et al., 1991; Trotter et al., 1991) .
These results have led to the concept, particularly in Japan, of using angiotensin II infusion for improving the delivery of chemotherapeutic drugs to tumours relative to normal tissues ('hypertension chemotherapy') (Suzuki et al., 1981; Sasaki et al., 1985; Takematsu et al., 1985; Noguchi et al., 1988; Anderson et al., 1991; Kobayashi et al., 1990 Kobayashi et al., & 1991 . Local intra-arterial administration of angiotensin II to hepatic tumours and liver metastases also has potential for improving regional chemotherapy of these tumours (Sasaki et al., 1985; Hemingway et al., 1991 and Goldberg et al., 1991 (Hori et al., 1985; Burton et al., 1985) . Trotter et al. (1991) One of the tail vein catheters was fitted with a T-piece connector allowing two syringes to be connected to it. The first syringe was held in a constant flow infusion pump and used to infuse angiotensin II (Sigma) at a rate of 0.2ml kg-' min-' into the rat's circulation. Aliquots of angiotensin II, which had been made up to a concentration of 200yg ml-' and stored at -20°C, were defrosted on each experimental day and were suitably diluted in 0.9% saline to give angiotensin II doses of between 0.02 and 0.5pgkg-' min-'.
Control rats were infused with 0.9% saline at the same rate. The second syringe contained 0.3 ml undiluted 'Euthatal' (May & Baker) for rapid killing of the rat at the end of the experiment.
The tail artery catheter was connected to a physiological pressure transducer (Gould) for measurements of mean arterial blood pressure throughout the infusion time. The second tail vein catheter was used to heparinise the rat (0.2 ml of 1000 units ml-' heparin (CP Pharmaceuticals Ltd)) and subsequently to connect a syringe held in a constant flow infusion pump set at a delivery rate of 0.6ml min-' for infusion of 0.37 MBq (10 jtCi) '251I-iodoantipyrine (1251I-IAP) ( Blood flow in mls g-' min-' was calculated, for each tissue, using tissue levels of 1251 or 14C measured by scintillation counting or autoradiography, arterial levels of 125I or 'IC measured by scintillation counting and the tissue-blood partition coefficient for IAP in each tissue (Tozer & Morris, 1990b) . Mathematical analysis was based on the sample principles as described in Tozer & Morris (1990b) . However, (1) arterial input curves (concentration of IAP in arterial blood vs time after start of infusion of IAP) were deconvolved to account for delay and dispersion of blood along the plastic catheters and (2) concentration of IAP vs time, for tissues, were obtained by convolution of the arterial input using the relationships derived by Kety (1960) . For each blood flow determination, convolutions were repeated for 200 possible blood flow values in order to produce a look-up table for tissue concentration of IAP vs blood flow. These methods will be published in detail elsewhere.
Tissue vascular resistance (TVR) was calculated from the relationship, TVR = perfusion pressure + blood flow. Venous pressure was taken to be insignificant compared to arterial pressure, such that measured mean arterial blood pressure was taken to be equivalent to perfusion pressure. Autoradiography Details of the autoradiographic procedure have been published in detail elsewhere (Tozer et al., 1990c) . Briefly, 20 Itm thick cryostat sections were cut at 1 mm intervals through each tumour and picked up onto coverslips. These were mounted onto cardboard sheets together with methyl methacrylate standards of known '4C activity (calibrated against 20 gm thick tumour sections of known '4C activity).
Autoradiograms were produced on autoradiographic film (Hyperfilm-pmax, Amersham) after exposure of several weeks. Adjacent frozen sections were picked up onto microscope slides, fixed and stained with haematoxylin and eosin for histological analysis.
Autoradiograms were analysed using an Applied Imaging image analysis system and 'WBA' software. Autoradiographic images (at least six per tumour) were captured by camera as optical density images and transformed pixel by pixel into blood flow images using the same mathematical analysis as described above. Blood flow measurements from viable or necrotic tumour regions were extracted from whole tumour sections by overlaying images of histology (captured by camera) onto corresponding blood flow images. Results were expressed as mean blood flow ± standard deviation for viable regions in each section. This corresponds to 1,000 to 12,000 pixel samples of blood flow per section. Results for groups of animals were expressed as means ± 1 standard error of the mean.
Results Figure 1 shows the relationship between tumour weight and blood flow in control, saline-infused rats for tumours from 5th to 10th passage away from the spontaneous tumour. There was a large variation in tumour blood flow from one rat to another but no overall change with increasing tumour weight within the range used for experiments. The mean flow for the whole group was 0.44 ml g-' min-' (n = 29 including three rats with unknown tumour weight). Tumours from four different passages were used in Figure 1 . Analysis of variance for these four transplants showed a highly significant variation in flow between them (P<0.0001). Mean and standard error blood flow for the separate transplants were 0.47 ± 0.04, 0.71 ± 0.04, 0.33 ± 0.04 and 0.34 ± 0.03 mls g1 min-'. That is, the standard errors are of the order of 10% of the means. This shows that the overall variation in tumour flow was mainly due to inter-transplant variation. In order to avoid bias in the data associated with this inter-transplant variation, the effects of angiotensin II were always assessed against controls from the same transplantation where intertumour variation in flow is minimal.
Three out of seven of the normal tissues studied (ileum, kidney and brain) also showed a significant, but smaller, variation from one experiment to the next (P = 0.02, 0.03 and 0.002 respectively). Control blood flow to the skin overlying the tumour, skin from the contralateral flank, skeletal muscle and heart showed no such variation. The pattern of variation in blood flow and vascular resistance between one experiment and the next was the same for ileum, kidney and brain but different from that in the tumour. This suggests that the variation in tumour blood flow was due to variation in the vascular architecture from one transplant group to another and not to environmental factors. The reasons for this variation are unknown.
Mean arterial blood pressure in anaesthetised, salineinfused rats varied between 80 and 100 mmHg. There was no relationship between pressure and tumour blood flow between these values. Figure 2 shows the effect of different doses of angiotensin II on mean arterial blood pressure measured at 20min after the start of angiotensin infusion. The pressure rises steeply with dose and plateaus at -0.2 jig kg-1 min-'. Some lung toxicity was observed in the rats. The highest angiotensin II dose (0.5 fg kg-' min-1) caused the rats some respiratory distress and, on postmortem, the lung tissue appeared oedematous. This was reflected by an increase in lung weight with angiotensin dose shown in Figure 3 . The straight line fit is highly significant but none of the individual points is statistically different Straight lines have been fitted to the data using weighted least squares regression. In Figure 4 , the decrease in blood flow with increasing blood pressure is significant at the 5% level (that is the fitted line fits the data better than a horizontal line through the mean for all points) for contralateral skin, muscle and kidney. The decreasing blood flow for skin overlying the tumour and ileum is on the borderline of significance (P = 0.09 and 0.10 respectively). Blood flow to the tumour, heart and brain shows no variation with increase in blood pressure.
Skin, kidney, ileum and skeletal muscle are the tissues most responsive to angiotensin II. Figure 5 shows that vascular resistance was increased by factors of between 2.5 and 5.0 for these tissues at the highest blood pressure. Such an increase would account for the large increase in mean arterial blood pressure shown in Figure 2 . Values above or below 1.0 in Figure 4 represent an increase or decrease in blood flow respectively, following administration of angiotensin II. Angiotensin II reduced tumour blood flow to about 80% of control values. This reduction was significant using the unpaired student's t-test (P = 0.01) if all tumours were grouped together. Since blood flow to the normal tissues tended to decrease with increase in blood pressure but blood flow to the tumour remained relatively constant, the differential between flow to tumour and normal tissue varied over the range of angiotensin doses used. For instance, blood flow to the skin overlying the tumour was 0.7 of its control flow at the lowest blood pressure compared to 0.8 for the tumour but only 0.35 compared to 0.8 for the tumour at the highest perfusion pressure. Blood flow to the heart showed a slight increase following angiotensin II (P= 0.01, Student's t-test for unpaired data) for all doses grouped together. The apparent increase in the brain was not significant even if all doses were grouped (P= 0.17). This is not surprising since the tight junctions of the brain endothelial layer are an effective barrier to angiotensin II. If vascular resistance remains constant, an increase in blood flow with increasing perfusion pressure follows from the relationship blood flow = perfusion pressure + vascular resistance. The fact that blood flow does not increase with blood pressure in any of the tissues studied, and actually decreases in some, means that vascular resistance must be increasing in all the tissues, including those in the tumour, heart and brain where there is no dose response for blood flow to angiotensin II. Figure 5 shows that this is generally the case. All the individual points in these graphs, except for the lowest dose of angiotensin II in the ileum and skeletal muscle, represent a significant increase in vascular resistance following angiotensin II administration (Student's t-test for unpaired data). The increase in tissue vascular resistance with increase in blood pressure is significant at the 5% level for contralateral skin and kidney. It is on the borderline of significance for skin overlying the tumour, ileum, skeletal muscle and brain (P = 0.09, 0.11, 0.06 and 0.06 respectively). Although vascular resistance in the tumour and heart tends to increase, this is not significant for the numbers of animals used (P = 0.19 and P = 0.21 respectively, Student's t-test for unpaired data). The increase in vascular resistance must be a direct response to angiotensin II in some tissues but could be a secondary response to an increase in blood pressure in other tissues such as the brain (i.e. autoregulation of blood flow in the face of an increase in perfusion pressure).
Autoradiograms of tumours were analysed in order to determine the effect of angiotensin II on the intra-tumour heterogeneity of blood flow. The coefficient of variation for all the individual pixel blood flow values within the viable regions of all the sections from each tumour was used as an index of heterogeneity. Figure 6 shows the coefficient of variation for different groups of angiotensin TI-treated rats relative to those for control rats. Although there is a tendency for the coefficient of variation to be lower after angiotensin II administration, none of the values is significantly different from 1.0 (Student's t-test for unpaired data). That is, the heterogeneity of blood flow within P22 tumours is neither increased nor decreased significantly following administration of angiotensin II. Further analysis of the autoradiograms did reveal some differences between tumours. The necrotic fraction varied from 0 to 12% of the surface area of individual tumour sections. Gross necrosis was always accompanied by negligible flow as previously described for the LBDS, tumour (Tozer et al., 1990c) and large regions of very low flow were absent in control tumours which were essentially viable throughout (six tumours). However, large, well-defined regions of very low flow were present in three out of 12 angiotensin II-treated tumours which were essentially viable. Figure 7a illustrates the relationship between blood flow and necrosis for the tumour with the largest necrotic fraction studied. Figure 7b illustrates a large, very low flow region 1. within an essentially viable tumour section from an angiotensin II treated rat.
A comparison of the effect of angiotensin II on blood flow to different regions within the tumours was also made. Figure  8 shows Mean arterial blood pressure (mmHg) 0.6 of the control value (P = 0.02) but not at all in sections cut from the tumour centre (P = 0.54). Thus the blood flow elatonshpbewee anitni I *idue inreae reduction to 0.8 of the control value in whole tumours pressure and the coefficient of variation for blood efficient of variation was calculated from the means (Figure 4) Mean arterial blood pressure (mmHg) Figure 8 Comparison , Tokuda et al., 1990 . The reasons for this discrepancy are unclear. The doses of angiotensin II used in our study tended to be lower than those used in other studies in order to avoid respiratory distress in our animals. However, the range of doses we used covered similar levels of induced hypertension, such that this difference seems an unlikely reason for the discrepancy. All our results were obtained at 20 min into the angiotensin II infusion time and so it is possible that we missed an increase in flow at earlier times. This also seems unlikely since Jirtle et al. found that the decrease in blood flow in their system was constant from 1 min after the start of infusion. Different tumours may respond differently to angiotensin II. Blood flow to the P22 tumour is relatively high and the necrotic fraction is low. We noted that the batch of tumours with the highest control blood flow reported here also showed the alrgest response to angiotensin II. Blood flow to tumours in the Jirtle study was even higher than for the P22 tumour (1.3 ml g-' min-'). Conversely, the subcutaneous tumours used in the Japanese studies, which consistently showed an improvement in blood flow following angiotensin II administration, had rather low pre-treatment blood flow (around 0.2mlmin-'g-1 for the AH109A tumour and the LY80 tumour, a Yoshida rat ascites hepatoma and a subline of the Yoshida sarcoma respectively) The reduction in blood flow for the P22 tumour is accompanied by an increase in vascular resistance which is of the same order as skeletal muscle and kidney. Assuming that angiotensin II does not affect viscosity of blood flowing through the tumour, the increase in vascular resistance represents significant tumour vasoconstriction. Ex vivo preparations of perfused P22 tumours have shown no vasoconstriction in response to an increase in perfusion pressure equivalent to that induced by angiotensin II (Sensky et al., manuscript submitted for publication). This suggests that the vasoconstriction is a direct effect of angiotensin II on the blood vessels supplying the tumour.
Previous authors have suggested that most tumours have very little capacity for responding directly to vasoactive agents (e.g. Trotter & Chaplin, 1991; Horsman et al., 1989) . This is certainly not the case for the P22 tumour. It is important to distinguish between those studies where blood flow was measured relative to the surrounding normal tissue and those where absolute blood flow was measured. An increase in the former, which has important implications, in itself, for delivery of chemotherapeutic agents to tumours, does not imply an increase in the latter. We found that angiotensin II increased tumour blood flow relative to various normal tissues but significantly decreased absolute flow. Other studies, in different tumour systems, have also shown a direct response of tumour blood vessels to vasoactive agents (Jirtle et al., 1978 , Weiss et al., 1986 , Tveit et al., 1987 .
All tested doses of angiotensin II reduced blood flow to the P22 tumour by a similar amount. These doses covered a range of perfusion pressures which suggests that angiotensin II increased tumour vascular resistance in a dose-dependent manner in order to overcome the tendency for blood flow to increase with increasing perfusion pressure. The results for tumour vascular resistance did show a trend towards a dose response but this was not statistically significant.
Our results for the effect of angiotensin II on blood flow heterogeneity are not readily comparable with other in the literature since those studies reported an overall increase, not decrease, in blood flow in their tumour systems (Hori et al., 1985; Trotter et al., 1991; Suzuki et al., 1991) . In the P22 tumour there was no difference in the overall intra-tumour heterogeneity of blood flow between control and angiotensin II-treated rats. This implies that angiotensin II is equally effective in reducing blood flow in the low flow regions as in the high flow regions when whole tumours are analysed. However, the reduction in blood flow at the highest perfusion pressure was due entirely to the response of the peripheral ANGIOTENSIN II MODIFICATION OF TUMOUR BLOOD FLOW 987 tumour regions. Blood flow to tumour sections cut from the tumour centre was unchanged. This suggests that there maybe some vascular collapse in the centre of the P22 tumour which the highest perfusion pressure could overcome. Vascular collapse may be more pronounced in the tumour centre than the periphery as a result of higher interstitial fluid pressure (Wiig et al., 1982; Boucher et al., 1990; Less et al., 1991) . Alternatively or, in addition, there may be a higher density of angiotensin II receptors at the periphery of these tumours than at the centre, possibly associated with a higher fraction of normal, incorporated vessels at the periphery than at the centre. The fact that large regions of very low flow, unconnected with necrosis, were observed in tumours from a minority of the angiotensin II-treated rats also suggests that there may be heterogeneous distribution of angiotensin II receptors in these tumours.
In summary, (1) The P22 tumour was found to be directly responsive to the vasonconstricting effects of angiotensin II. The response was of the same order as that in skeletal muscle and kidney.
(2) The vasoconstriction outweighed the effect of an increase in perfusion pressure, induced by angiotensin II, resulting in a decrease in tumour blood flow. (3) Overall, the intra-tumour heterogeneity of blood flow was not altered by angiotensin II, although, for the highest perfusion pressure studied, the reduction in overall tumour blood flow was due entirely to the response of the tumour periphery. In a minority of treated tumours, large areas of very low flow were observed. These regions were not related to necrosis. (4) These results suggest that tumours other than the P22 could also respond directly to angiotensin II and other vasoactive agents. Analysis of inter-and intratumour heterogeneity of angiotensin II receptor number, determination of the ratio of normal to new blood vessels within tumours and measurement of physiological tumour parameters such as microvascular pressure and interstitial fluid pressure is a rational approach to finding a method for predicting tumour blood flow response. VAUPEL, P. (1975) . Interrelationship between mean arterial blood pressure, blood flow and vascular resistance in solid tumor tissue of DS-carcinosarcoma. Experentia, 31, 587. WEISS, L., TVEIT, E., JANSSON, I. & HULTBORN, R. (1986 
